The News
Catch the latest updates as CTMC drives innovation in cell therapy to accelerate development and manufacturing
to impact patients sooner
Press Releases
CTMC Reaches Pivotal-Stage TIL Manufacturing Milestone and Expands Proprietary TIL Platform
A partner tumor-infiltrating lymphocyte (TIL) program has advanced into pivotal-stage manufacturing at CTMC, demonstrating CTMC's ability to support...
QIMR Berghofer and CTMC announce strategic collaboration in cell and gene therapy through the CTMC Global Network Alliance
BRISBANE, AUSTRALIA & HOUSTON, TEXAS, 23 JUNE 2026 – QIMR Berghofer and CTMC, a joint venture between Resilience and The University of Texas MD...
Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies
The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas UT MD Anderson received Investigational New Drug clearance from the Food...
Recent News
Bigger in Texas: Spilling the secrets on Houston’s biomanufacturing boom
An industry expert told us how recent projects in Houston speak to the city’s drive to become a premier biomanufacturing hub. Read the full article...
The Biggest Bottlenecks Holding Back Cell and Gene Therapy
Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges Read more...
FDA’s Manufacturing Registration Rule’s Impact on Advanced Therapies: Part 2
In part 2 of this 2-part interview, Jason Bock, founder and CEO of CTMC provides input on how the FDA's proposed manufacturing registration rule may...
FDA’s Manufacturing Registration Rule’s Impact on Advanced Therapies: Part 1
Jason Bock, founder and CEO of CTMC, provides his perspective on the FDA’s proposed rule to streamline registration for single distributed...
The Medicine Maker 2026 Power List
Celebrating 60 inspirational individuals – across small molecules, biopharma, and cell and gene therapy – who are helping to translate pharma’s...
Overcoming Raw Material Variability Challenges for Autologous Adoptive Cell Therapies
Patient apheresis heterogeneity from prior systemic therapy, collection settings, anticoagulants, timing, and transport/cryopreservation cannot be...
Do you expect continued movement away from one-stop-shop outsourcing toward deeper modality-specific expertise?
Read the perspectives of industry experts here: Pharma's Almanac
The Wealthing Podcast
Alicia Castillo Holley hosts Jason Bock on her show. Curative Intent: on Engineering T-Cells, Patient Impact, and Chasing the Impossible. The...
Organizing Digital Systems Around Novel Modalities
By Jason Bock, Ph.D., CEO, and Duane Avant, CTO, CTMC Manufacturing autologous cell therapies requires close coordination with clinical staff, as...